Mazor Robotics Ltd. Expands Leadership Organization

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and leader in the field of surgical guidance systems, today announced leadership additions and organizational steps to position the company for its next phase of growth.

According to Mr. Ori Hadomi, CEO of Mazor Robotics Ltd., “In 2016, we announced and set in motion a plan to accelerate growth with the signing of strategic agreements and the launch of the transformative Mazor X platform. The new hires complement the capabilities of the existing team, positioning Mazor for additional growth opportunities as well as leading our more than 200 employees. I believe that our expanded leadership team maximizes Mazor’s near and long term potential.”

The Company has formed an integrated Product Development Group combining the current R&D and Product groups into a unified department. The newly formed Product Development group creates operational synergy to address market needs and to continue development of innovative spine products and future product enhancements. The department is to be headed by Oren Zarchin, Ph.D. who joins Mazor in the role of Vice President, Product Development. Dr. Zarchin’s most recent position was as Director at Philips Healthcare leading multi-disciplinary R&D teams and product platforms. This change is effective August 1, 2017.

In addition, Mazor has established the Advanced Technology Group and Mr. Eli Zehavi is appointed Executive Vice President of Advanced Technologies. Mr. Zehavi is a co-founder of Mazor and has served as the company’s Executive Vice President, Research and Development and Chief Operating Officer, since the company’s founding. The Advanced Technology Group is expected to leverage Mazor’s vast experience and expertise in software and precision guidance to develop non-spine patient focused innovations. This change is effective August 1, 2017.

Mazor has also created a new position, Vice President of Operations and Service, and recruited Mr. Joshua Belkar, an industry veteran with more than 20 years of experience in the medical device industry including a long tenure at Medtronic (Given Imaging) as Director of Operations. Mr. Belkar’s experience implementing and leading operations processes that directly impact quality will contribute to the increase in effective production as demand for Mazor systems and products rises. He will also lead the effort to expand and solidify Mazor’s first tier global service organization with a strong emphasis on global responsiveness and customer satisfaction. This change is effective July 16, 2017.

The Company also announced expanded roles and responsibilities for Ms. Sharon Levita, Chief Financial Officer and Mr. Christopher Prentice, CEO of Mazor Inc. (US Subsidiary). Ms. Levita, in addition to her CFO responsibilities has been named CFO & Vice President, Business Operations, and is overseeing a finance and additional business teams that provides enabling services to the corporation. Mr. Prentice has been named Chief Commercial Officer, consolidating the global commercial activity of the Company. These two changes are effective immediately.



Subscribe to Medical Device News Magazine

Related Articles